BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 23466817)

  • 21. MicroRNA expression profiles of esophageal cancer.
    Feber A; Xi L; Luketich JD; Pennathur A; Landreneau RJ; Wu M; Swanson SJ; Godfrey TE; Litle VR
    J Thorac Cardiovasc Surg; 2008 Feb; 135(2):255-60; discussion 260. PubMed ID: 18242245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma.
    Snider EJ; Compres G; Freedberg DE; Khiabanian H; Nobel YR; Stump S; Uhlemann AC; Lightdale CJ; Abrams JA
    Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1687-1693. PubMed ID: 31466948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.
    Lord RV; Salonga D; Danenberg KD; Peters JH; DeMeester TR; Park JM; Johansson J; Skinner KA; Chandrasoma P; DeMeester SR; Bremner CG; Tsai PI; Danenberg PV
    J Gastrointest Surg; 2000; 4(2):135-42. PubMed ID: 10675236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
    Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ
    Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ROLE OF MICRORNA IN PREDICTING OF ADENOCARCINOMA DEVELOPMENT IN BARRETT’S ESOPHAGUS.
    Tsitskarava AZ; Zaraiskiy MI; Vasilevskiy DI; Lapshin AS; Popova VF; Smirnov AA; Lyubchenko ME
    Vestn Khir Im I I Grek; 2016; 175(4):13-4. PubMed ID: 30457256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of C1q complement component in Barrett's esophagus and esophageal adenocarcinoma.
    Bobryshev YV; Lu J; Lord RV
    J Gastrointest Surg; 2010 Aug; 14(8):1207-13. PubMed ID: 20496011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic alterations in malignant transformation of Barrett's esophagus.
    Riegman PH; Vissers KJ; Alers JC; Geelen E; Hop WC; Tilanus HW; van Dekken H
    Cancer Res; 2001 Apr; 61(7):3164-70. PubMed ID: 11306503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
    Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus.
    Dolan K; Garde J; Walker SJ; Sutton R; Gosney J; Field JK
    Hum Pathol; 1999 Dec; 30(12):1508-14. PubMed ID: 10667431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
    Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma.
    Hao Y; Triadafilopoulos G; Sahbaie P; Young HS; Omary MB; Lowe AW
    Gastroenterology; 2006 Sep; 131(3):925-33. PubMed ID: 16952561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CDKN2A-p16 Deletion and Activated KRAS
    Sun J; Sepulveda JL; Komissarova EV; Hills C; Seckar TD; LeFevre NM; Simonyan H; Young C; Su G; Del Portillo A; Wang TC; Sepulveda AR
    Cell Mol Gastroenterol Hepatol; 2024; 17(5):769-784. PubMed ID: 38296052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cross sectional study of p504s, CD133, and Twist expression in the esophageal metaplasia dysplasia adenocarcinoma sequence.
    Ahmad J; Arthur K; Maxwell P; Kennedy A; Johnston BT; Murray L; McManus DT
    Dis Esophagus; 2015 Apr; 28(3):276-82. PubMed ID: 24612412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus.
    Guillem P; Billeret V; Buisine MP; Flejou JF; Lecomte-Houcke M; Degand P; Aubert JP; Triboulet JP; Porchet N
    Int J Cancer; 2000 Dec; 88(6):856-61. PubMed ID: 11093805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma.
    Kan T; Meltzer SJ
    Curr Opin Pharmacol; 2009 Dec; 9(6):727-32. PubMed ID: 19773200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of miRNAs and genes for predicting Barrett's esophagus progressing to esophageal adenocarcinoma using miRNA-mRNA integrated analysis.
    Yao C; Li Y; Luo L; Xiong Q; Zhong X; Xie F; Feng P
    PLoS One; 2021; 16(11):e0260353. PubMed ID: 34818353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A microRNA Signature Identifies Patients at Risk of Barrett Esophagus Progression to Dysplasia and Cancer.
    Saller J; Jiang K; Xiong Y; Yoder SJ; Neill K; Pimiento JM; Pena L; Corbett FS; Magliocco A; Coppola D
    Dig Dis Sci; 2022 Feb; 67(2):516-523. PubMed ID: 33713247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis.
    Fassan M; Pizzi M; Battaglia G; Giacomelli L; Parente P; Bocus P; Ancona E; Rugge M
    J Clin Pathol; 2010 Aug; 63(8):692-6. PubMed ID: 20702469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of the current understanding and clinical utility of miRNAs in esophageal cancer.
    Sakai NS; Samia-Aly E; Barbera M; Fitzgerald RC
    Semin Cancer Biol; 2013 Dec; 23(6 Pt B):512-21. PubMed ID: 24013023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The molecular genetic alterations in mucosa of intestines as markers of oncologic progression and estimate of effectiveness of anti-reflux operations in patients with Barrett's esophagus].
    Osminin SV; Vetshev FP; Rudenko VV; Zaletaev DV; Khorobrykh TV; Nemtsova MV
    Klin Lab Diagn; 2016 Oct; 61(10):681-5. PubMed ID: 30615323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.